Abdelrahman Fatma, Easwaran Maheswaran, Daramola Oluwasegun I, Ragab Samar, Lynch Stephanie, Oduselu Tolulope J, Khan Fazal Mehmood, Ayobami Akomolafe, Adnan Fazal, Torrents Eduard, Sanmukh Swapnil, El-Shibiny Ayman
Center for Microbiology and Phage Therapy, Biomedical Sciences, Zewail City of Science and Technology, Giza 12578, Egypt.
Department of Biomedical Engineering, Sethu Institute of Technology, Tamil Nadu 626115, India.
Antibiotics (Basel). 2021 Jan 28;10(2):124. doi: 10.3390/antibiotics10020124.
Due to the global emergence of antibiotic resistance, there has been an increase in research surrounding endolysins as an alternative therapeutic. Endolysins are phage-encoded enzymes, utilized by mature phage virions to hydrolyze the cell wall from within. There is significant evidence that proves the ability of endolysins to degrade the peptidoglycan externally without the assistance of phage. Thus, their incorporation in therapeutic strategies has opened new options for therapeutic application against bacterial infections in the human and veterinary sectors, as well as within the agricultural and biotechnology sectors. While endolysins show promising results within the laboratory, it is important to document their resistance, safety, and immunogenicity for application. This review aims to provide new insights into the synergy between endolysins and antibiotics, as well as the formulation of endolysins. Thus, it provides crucial information for clinical trials involving endolysins.
由于全球范围内抗生素耐药性的出现,围绕内溶素作为一种替代疗法的研究有所增加。内溶素是噬菌体编码的酶,成熟的噬菌体病毒粒子利用它从内部水解细胞壁。有大量证据证明内溶素能够在没有噬菌体协助的情况下在外部降解肽聚糖。因此,将它们纳入治疗策略为人类和兽医领域以及农业和生物技术领域对抗细菌感染的治疗应用开辟了新的选择。虽然内溶素在实验室中显示出有希望的结果,但记录它们在应用中的耐药性、安全性和免疫原性很重要。本综述旨在提供关于内溶素与抗生素之间协同作用以及内溶素制剂的新见解。因此,它为涉及内溶素的临床试验提供了关键信息。